GeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 1,285 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,285 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $84.22, for a total transaction of $108,222.70. Following the sale, the chief financial officer directly owned 41,476 shares of the company’s stock, valued at $3,493,108.72. The trade was a 3.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, June 16th, Kevin Feeley sold 3,729 shares of GeneDx stock. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33.

GeneDx Stock Performance

WGS opened at $85.26 on Friday. The company’s 50 day moving average is $74.67 and its 200 day moving average is $66.78. The company has a current ratio of 3.30, a quick ratio of 3.06 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -23.42 and a beta of 1.99. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, August 3rd. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.20. GeneDx had a negative net margin of 23.41% and a positive return on equity of 4.12%. The business had revenue of $114.44 million during the quarter, compared to analysts’ expectations of $111.01 million. During the same period in the prior year, the company earned $0.36 earnings per share. On average, equities research analysts predict that GeneDx Holdings Corp. will post -0.41 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on WGS. Wall Street Zen raised GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Piper Sandler reissued an “overweight” rating and set a $63.00 price target (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. BTIG Research restated a “buy” rating and issued a $90.00 price target on shares of GeneDx in a research report on Tuesday, August 4th. Guggenheim reaffirmed a “buy” rating and issued a $74.00 price objective (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $89.57.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently modified their holdings of WGS. Kestra Advisory Services LLC bought a new position in GeneDx in the 4th quarter worth $27,000. Fifth Third Bancorp bought a new stake in GeneDx during the first quarter valued at about $31,000. Quarry LP raised its holdings in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after acquiring an additional 209 shares during the period. Ramirez Asset Management Inc. purchased a new position in shares of GeneDx in the fourth quarter valued at about $33,000. Finally, Greenline Wealth Management LLC purchased a new position in shares of GeneDx in the fourth quarter valued at about $33,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease.

Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants.